Our data is consistent with studies from the Blazar group, which investigated the role of other inhibitory molecules such as CTLA-4, PD-1, and, most recently, Tim-3, in limiting the alloresponse in GVHD [28], [29]. The gene discussed is HAVCR2; the disease is graft versus host disease.